BC
PHAT icon

Birchview Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Birchview Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Sell
55,000
-140,000
-72% -$1.6M 0.28% 50
2026
Q1 		$2.17M Hold
195,000
– – 1.23% 23
2025
Q4 		$3.24M Buy
195,000
+110,000
+129% +$1.57M 1.89% 16
2025
Q3 		$1M Buy
85,000
+60,000
+240% +$619K 0.76% 38
2025
Q2 		$240K Buy
+25,000
New +$138K 0.24% 57

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Birchview Capital's PHAT Position: Q2 2026 in Review

Birchview Capital reduced its Phathom Pharmaceuticals (PHAT) stake by 72% in Q2 2026, selling an estimated $1.6M and leaving 55,000 shares worth $597K. The position accounts for 0.28% of the portfolio, ranked #50.

Birchview Capital first reported a position in PHAT in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.24M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Birchview Capital held 55,000 shares of Phathom Pharmaceuticals worth $597K as of Q2 2026.
  • Birchview Capital sold 140,000 Phathom Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
  • Phathom Pharmaceuticals made up 0.28% of Birchview Capital's portfolio in Q2 2026, its #50 holding.
  • Birchview Capital first reported a position in Phathom Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Birchview Capital's Phathom Pharmaceuticals position peaked at $3.24M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.